Mast cells in renal inflammation and fibrosis: Lessons learnt from animal studies

Madjène, Lydia Celia; Pons, Maguelonne; Danelli, Luca; Claver, Julien; Ali, Liza; Madera-Salcedo, Iris K.; Kassas, Asma; Pellefigues, Christophe; Marquet, Florian; Dadah, Albert; Attout, Tarik; El-Ghoneimi, Alaa; Gautier, Grégory; Benhamou, Marc; Charles, Nicolas; Daugas, Éric; Launay, Pierre; Blank, Ulrich

doi:10.1016/j.molimm.2014.03.002

Cited by 41 publications

(43 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, previous examinations in various renal or other disease models were unable to distinguish their role during acute and chronic phases, as they were based on c-Kitdependent animal models of constitutive MC deficiency (22,(52)(53)(54). Exploiting the property of RMB mice to delete MCs after the acute injury phase by a change in the timing of DT administration allowed us to overcome this disadvantage and to look at their contribution during the chronic phase.…”

Section: Discussionmentioning

confidence: 99%

Early Phase Mast Cell Activation Determines the Chronic Outcome of Renal Ischemia–Reperfusion Injury

Danelli

Madjène

Madera-Salcedo

et al. 2017

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Ischemia–reperfusion injury (IRI) is an important cause of acute kidney injury that can lead to end-stage renal failure. Although the ensuing inflammatory response can restore homeostasis, a consecutive maladaptive repair and persistent inflammation represent important risk factors for postischemic chronic kidney disease development. In this study, we investigated the role of mast cells in both the early and late phases of the inflammatory response in experimental models of acute and chronic renal IRI using our recently developed mouse model that allows conditional ablation of mast cells. Depletion of mast cells prior to IRI resulted in improved renal function due to diminished local inflammatory cytokine/chemokine levels and neutrophil recruitment to the kidneys after the acute injury phase (48 h post-IRI). Furthermore, although not completely protected, mast cell–depleted mice displayed less organ atrophy and fibrosis than did wild-type mice during the chronic phases (2 and 6 wk post-IRI) of disease development. Conversely, mast cell ablation after the acute phase of IRI had no impact on organ atrophy, tubular necrosis, or fibrosis. Thus, our results suggest a deleterious role of mast cells during the acute inflammatory phase of IRI promoting subsequent fibrosis development, but not during the chronic phase of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Early Phase Mast Cell Activation Determines the Chronic Outcome of Renal Ischemia–Reperfusion Injury

Danelli

Madjène

Madera-Salcedo

et al. 2017

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most studies have suggested that a reduction of mast cells, or their typical enzyme chymase, increases fibrosis (52)(53)(54)(55)(56), whereas others suggest the opposite (57,58). Thus, the potential therapeutic value of mast cell manipulation in fibrosis is uncertain (23,59).…”

Section: The Role Of Immune Cellsmentioning

confidence: 99%

Renal Allograft Fibrosis: Biology and Therapeutic Targets

Floege

2015

American Journal of Transplantation

View full text Add to dashboard Cite

“…Firstly, the involvement of mast cells may not be specific for autoimmune renal disease. Be cause besides lupus nephritis, the involvement of mast cells in renal inflammation and fibrosis has been reported in various kidney diseases including diabetic nephropathy [29] . Secondarily, some studies in human and mice showed no correlation between mast cell and lupus nephritis.…”

Section: Mast Cells In Systemic Lupus Erythema Tosusmentioning

confidence: 99%

Mast cells in collagen diseases

Mikita

Inaba²,

Yoshimasu³

et al. 2017

Trends Immunother

View full text Add to dashboard Cite

Mast cells are involved in many immune reactions and diseases through 1) the expressions of several receptors, 2) productions of various mediators such as histamine, cytokines, and chemokines, 3) direct in teractions with immune cells. Besides allergic diseases, the involvement of mast cells has been also in vestigated in autoimmune diseases such as bullous pemphigoid, rheumatoid arthritis, and multiple sclerosis. Moreover, several studies reported the involvement of mast cells in collagen diseases. In this article, we review recent findings about the role of mast cells especially in systemic lupus erythematosus and systemic sclerosis. In these diseases, mast cells seem to be involved in local inflammation and tissue damage in the targeted organ or local immunosuppression rather than the development of autoimmunity including production of autoantibodies.

show abstract

Mast cells in renal inflammation and fibrosis: Lessons learnt from animal studies

Cited by 41 publications

References 71 publications

Early Phase Mast Cell Activation Determines the Chronic Outcome of Renal Ischemia–Reperfusion Injury

Early Phase Mast Cell Activation Determines the Chronic Outcome of Renal Ischemia–Reperfusion Injury

Renal Allograft Fibrosis: Biology and Therapeutic Targets

Mast cells in collagen diseases

Contact Info

Product

Resources

About